The Life Sciences and M&A teams advised Chiasma, Inc. (Nasdaq: CHMA) on its definitive agreement to be acquired by Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) in an all-stock combination.
Chiasma is a commercial stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases.
Amryt is a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases.
Under the terms of the transaction, each share of Chiasma common stock issued and outstanding prior to the consummation of the transaction will be exchanged for 0.396 Amryt American Depositary Shares (“ADSs”), each representing five Amryt ordinary shares. As of the close of trading on May 4, 2021 Amryt’s ordinary shares on AIM were £2 ($2.78) per share and Amryt’s ADS’s on Nasdaq were $12.95 (£9.31) per ADS.
The Goodwin team was led by Michael Bison, Lillian Kim, Jim Matarese, Tevia Pollard, Will Stanton, Jamila Hollins, and Adanna Uwazurike (M&A), and included Dan Lang, Tim Hurley, and Ally Gao (ongoing corporate); Alex Apostolopoulos and Gregg Coughlin (Tax); Sarah Bock, Morgan Frisoli, Jen Luz (Litigation); Cathy McCarty and Bonnie Choi (Intellectual Property); Paul Jin (Antitrust); Stephanie Philbin (FDA); Jake Osborn and Amy Josselyn (Global Trade); Tim Holahan, Ana Victoria Alvarado, Jackie Klosek and Paul Thompson (Privacy); Andrew Harrow (UK Life Sciences); Roger Cohen, Heath Roosevelt Ingram.
For more details, read the press release and articles in Seeking Alpha, Proactive Investor, and Business Insider.